The Role of Bisphosphonates in Malignant Bone Pain: A Review

Galasko CSB . Skeletal metastases. Clin Orthoped 1986; 210: 18–30.

Nielson OS , Munro AJ , Tannock IF . Bone metastases: pathophysiology and management policy. J Clin Oncol 1991; 9: 509–524.

Vainio A , Auvinen A , Prevalence of symptoms among patients with advanced cancer: an international collaborative study. J Pain Sympt Manag 1996; 12: 3–10.

Fidler M. Incidence of fracture through metastases in long bones. Acta Orthop Scand 1981; 52: 623–627.

Grant Ft , Papadopoulos SM , Sandler HM , Greenberg HS . Metastatic epidural spinal cord compression: current concepts and treatment. J Neurol-Oncol 1994; 19: 79–92.

Ralston SH . Management of cancer-associated hypercalcemia. Eur J Palliat Care 1994; 1: 170–174.

Levy M. Pharmacological treatment of cancer pain. N Engl J Med 1996; 335: 1124–1132.

Cancer Pain Relief. 2nd edition. Geneva, Switzerland: World Health Organization, 1996.

Pereira J. The management of cancer bone pain. Topics in Palliative Care, Volume 3. In: Portenoy R , Bruera E (eds). New York: Oxford University Press, 1998 (in press).

Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997; 69: 1–18.

Hanks GW . Pharmacological treatment of bone pain. Cancer Surv 1988; 7: 87–101.

Pace V. Use of non-steroidal anti-inflammatory drugs in cancer. Palliat Med 1995; 9: 273–286.

Eisenberg E , Berkey CS , Carr DB , Efficacy and safety of nonsteroidal anti-inflammatory drugs for cancer pain: a meta-analysis. J Clin Oncol 1994; 12: 2756–2765.

McQuay HJ , Carrol D , Moore RA . Radiotherapy for painful bone metastases: a systematic review. Clin Oncol 1997; 9: 150–154.

Price P , Hoskin PJ , Easton D , Prospective randomized trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. Radiother Oncol 1986; 6: 247–255.

Cole DJ . A randomized trial of 4 Gy or 8 Gy single doses in the treatment of metastatic bone pain. Radiother Oncol 1988; 12: 297–300.

Wood BC . Hormone treatments in the common “hormone dependent” carcinomas. Palliat Med 1993; 7: 257–272.

Gallagher CJ . Cancer of the prostate. Brit Med J 1994; 308: 780–784.

Kearsley JH . Some basic guidelines in the use of chemotherapy for patients with incurable malignancy. Palliat Med 1994; 8: 11–17.

Twycross R. The risks and benefits of corticosteroids in advanced cancer. Drug Safety 1994; 11: 163–178.

Rosier RN . Orthopedic management of cancer pain. In: Pratt RB (ed). Cancer Pain. Philadelphia: J.B. Lippincott, 1993; pp. 461–468.

Cherny N , Arbit E , Jain S. Invasive techniques in the management of cancer pain. In: Cherny N , Foley KM (eds). Hematology/Oncology Clinics of North America: Pain and Palliative Care 1996; 10: 121–137.

Bennett A. The role of biochemical mediators in peripheral nociception and bone pain. Cancer Surv 1988; 7: 55–67.

Mundy GR . Mechanisms of osteolytic bone destruction. Bone 1991; 12(Suppl. 1): S1–S6.

Body JJ . Pathophysiology of osteolysis: the putative mode of action of bisphosphonates. Eur J Palliat Care 1994; 1: 116–120.

Kanis JA , McCloskey EV , Taube T , O'Rourke N. Rationale for the use of bisphosphonates in bone metastases. Bone 1991; 12(Suppl. 1): S13–S18.

Coleman RE , Purohit OP . Osteoclast inhibition for the treatment of bone metastases. Cancer Treat Rev 1993; 19: 79–103.

Body JJ , Coleman RE , Piccart M. Use of bisphosphonates in cancer patients. Cancer Treat Rev 1996; 22: 265–287.

Warrell RP , Lovett D , Dilmarian FA , Low-dose gallium nitrate for prevention of osteolysis in myeloma: results of a pilot randomized study. J Clin Oncol 1993; 11: 2443–2446.

Kanis JA , O'Rourke N , McCloskey EV . Consequences of neoplasia-induced bone resorption and the use of clodronate. Int J Oncol 1994; 5: 713–731.

Fitton A , McTavish D. Pamidronate: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 1991; 41: 289–318.

Sahni M , Guenther HL , Fleisch H , Collin P , Martin TJ . Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 1993; 91: 2004–2011.

Lacroix M , Siwek B , Body JJ . Effects of secretory products of breast cancer cells on osteoblast-like cells. Breast Res Treat 1996; 38: 209–216.

Ernst DS , MacDonald N , Paterson AHG , Jenson J , Brasher P , Bruera E. A double-blind, crossover trial of intravenous clodronate in metastatic bone pain. J Pain Sympt Manag 1992; 7: 4–11.

Elomaa I , Blomquist C , Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet 1983; 1: 146–149.

Adami S , Miar M. Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma. Cancer Res 1989; 116: 67–72.

Merlini G , Parrinello GA . Long-term effect of parenteral dichloromethylene bisphosphonate on bone disease of myeloma patients treated with chemotherapy. Hema Oncol 1990; 8: 23–30.

Robertson AG , Reed NS , Ralston SH . Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study. J Clin Oncology 1995; 13: 2427–2430.

Vorreuther R. Bisphosphonates as an adjunct to palliative therapy of bone metastases from prostate carcinoma. A pilot study on clodronate. Brit J Urol 1993; 72: 792–795.

Lahtinen R , Laakso M , Palva I , Randomized, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 1992; 340: 1049–1052.

Ernst DS , Brasher P , Hagen N , A randomized, controlled trial of intravenous clodronate in patients with metastatic bone disease and pain. J Pain Sympt Manag 1997; 13: 319–326.

Purohit OP , Anthony C , Radstone CR , Owen J , Coleman RE . High-dose intravenous pamidronate for metastatic bone pain. Brit J Cancer 1994; 70: 554–558.

Thurlimann B , Morant R , Jurgi WF , Radziwill A. Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study. Support Care Cancer 1994; 2: 61–65.

Purohit OP , Radstone CR , Anthony C , A randomized double-blind comparison of intravenous pamidronate and clodronate in the hypercalcemia of malignancy. Brit J Cancer 1995; 72: 1289–1293.

Vinholes J , Guo C-Y , Purohit OP , Metabolic effects of pamidronate in patients with metastatic bone disease. Brit J Cancer 1996; 73: 1089–1095.

Coleman RE , Woll PJ , Miles M , Treatment of bone metastases from breast cancer with 3-amino-1, 1-hydroxypropylidene bisphosphonate. Brit J Cancer 1988; 58: 621–5.

Morton AR , Cartnill JA , Pillai GV , Sclerosis of lytic bone metastases after disodium amino-hydroxypropylidene bisphosphonate in patients with breast carcinoma. Brit Med J 1988; 297: 772–773.

Lipton A , Glover D , Harvey H , Grabelsky S , Pamidronate in the treatment of bone metastases: results of 2 dose-ranging trials in patients with breast or prostate cancer. Ann Oncol 1994; 5 (Suppl. 7): 531–535.

Thiebaud D , Leyvraz S , von Fliedner V , Treatment of bone metastases from breast cancer and myeloma with pamidronate. Eur J Cancer 1991; 27: 37–41.

Glover D , Lipton A , Keller A , Intravenous pamidronate disodium treatment for bone metastases in patients with breast cancer a dose-seeking study. Cancer 1994; 74: 2949–2955.

Clarke NW , Holbrook J , Osteoclast inhibition by pamidronate in metastatic prostate cancer: a preliminary study. Brit J Cancer 1991; 63: 420–423.

Paterson AHG , Powles TJ , Kanis JA , Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11: 59–65.

van Holten-Verzantvoort ATM , Kroon HM , Bijvoet OLM , Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11: 491–498.

Conte PF , Latreille J , Mauriac F , Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized control trial. J Clin Oncol 1996; 14: 2552–2559.

van Holten-Verzantvoort ATM , Hermans J , Beex L , Does supportive pamidronate treatment prevent or delay the first manifestations of bone metastases in breast cancer patients? Eur J Cancer 1996; 32A: 450–454.

Hacking A , Gudgeon CA , MacNaughton D , Dent DM . Pamidronate (APD) as single infusion monotherapy in the treatment of bone metastases from breast cancer. In: Bijvoet OLM , Lipton A (eds). Osteoclast Inhibition in the Management of Malignancy-Related Bone Disorders. Lewiston, New York: Hogrefe and Huber, 1991; pp. 45–53.

Belch AR , Bergsagel DE , Wilson K , Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol 1991; 9: 1397–1402.

Coleman R , Purohit K , Vinholes J. New roles for bisphosphonates in cancer therapy. Progress Palliat Care 1996; 4: 39–43.

McClosky EV , MacLennan ICM , Drayson M , Chapman C , Dunn J , Kanis JA . Effect of clodronate on progression of skeletal disease in multiple myelomatosis. Eur J Cancer 1995; 31A(Suppl 5): 162.

Elomaa I , Kylmala T , Tammela T , Effect of oral clodronate on bone pain: a controlled study in patients with metastatic prostate cancer. Int Urol Nephrol 1992; 24: 159–166.

Jung A , Chantraine A , Donath A Use of dichloromethylene diphosphonate in metastatic bone disease. N Engl J Med 1983; 308: 1499–1501.

Vinholes J , Guo C-Y , Purohit OP , Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy. J Clin Oncol 1997; 15: 131–138.

Ralston SH , Gallacher SJ , Patel U , Comparison of three intravenous bisphosphonates in cancer-associated hypercalcemia. Lancet 1989; 2: 1180–1182.

Cascinu S , Casadei V , Del Forro E , Alexxandroni P , Catalano G. Pamidronate in patients with painful bone metastases, who failed initial treatment with hormones and/or chemotherapy. Support Care Cancer 1996; 4: 31–33.

Clemens MR , Fessele K , Heim ME . Multiple myeloma: effect of daily dichloromethylene bisphosphonate on skeletal complications. Ann Hematol 1993; 141–146.

Burkhardt P , Thiebarrd D , Perey L , van Fliedner V. Treatment of tumor-induced osteolysis by APD. Recent Results Cancer Res 1989; 116: 54–66.

Koenders PG , Beex L , Kloppenborg P , Smals A , Benraad T. Human breast cancer: survival from metastases. Breast Cancer Res Treat 1992; 21: 173–180.

Berenson JR , Lichterstein A , Porter L , Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996; 334: 488–493.

van Holten-Verzantvoort ATM , Bijvoet OLM , Cleton FJ , Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. Lancet 1987; ii: 983–985.

van Holten-Verzantvoort ATM , Zwinderman AH , Aaronson NK , The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer patients. Eur J Cancer 1991; 27: 544–549.

Hortobagyi GN , Thierault RL , Porter L , Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996; 335: 1785–1791.

Elomaa I , Blomquist C , Porkka L , Treatment of skeletal disease in breast cancer: a controlled clodronate trial. Bone 1987; 8(Suppl. 1): 53–56.

Kanis JA , Powles T , Paterson AHG , Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 1996; 19: 663–667.

Man Z , Otero AB , Rendo P , Use of pamidronate for multiple myeloma osteolytic lesions. Lancet 1990; 335: 663.

Dowell DJ , Howell A , Morton A , Daley-Yates PT , Hoggarth CR . Pamidronate (APO) treatment of skeletal metastases from breast cancer. In: Rubens RD (ed). The Management of Bone Metastases and Hypercalcemia by Osteoclast Inhibition. Bern, Switzerland: Hogrefe and Huber, 1990: pp. 76–80.

Pigott KH , Baddeley H , Maher EJ . Pattern of disease in spinal cord compression on MRI scan and implications for treatment. Clin Oncol 1994; 6: 7–10.

Tyrrell CJ . Role of Pamidronate in the management of bone metastases from breast cancer: results of a noncomparative multicenter Phase II trial. Ann Oncol 1994; 5(Suppl. 7): 37–40.

McIntyre E , Bruera E. Symptomatic hypocalcemia after intravenous pamidronate. J Palliat Care 1996; 12: 46–47.

Plosker GL , Goa KL . Clodronate: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 1994; 47: 945–982.

Pecherstorfer M , Zuzana H , Jean-Jacques B , Randomized Phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J Clin Oncol 1996; 14(1): 268–276.

Tyrrell CJ , Madsen EL , Collinson M , A study of renal function after four infusions of pamidronate 90 mg given over 60 minutes one week apart. Eur J Cancer 1991; 29A(Suppl. 6): 282.

Walker P , Watanabe S , Lawlor P , Hanson J , Pereira J , Bruera E. Subcutaneous clodronate: a study evaluating efficacy in hypercalcemia of malignancy. Ann Oncol 1997; 8: 915–916.

Daley-Yates PT , Dodwell DJ , Pongchaidecha M , The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases. Calcif Tissue Int 1991; 49: 433–435.

Degroen PC , Lubbe DF , Hirsch L , Esophagitis associated with the use of alendronate. N Engl J Med 1996; 335: 1016–1021.

Biermann WA , Cantor RI , Fellin FM , An evaluation of the potential cost reductions resulting from the use of clodronate in the treatment of metastatic carcinoma of the breast bone. Bone 1991; Suppl. 1: S37–S42.

den Daas N. Estimating length of survival in end-stage cancer: a review of the literature. J Pain Sympt Manag 1995; 10(7): 548–555.

Richards MA , Braysher S , Gregory WM , Advanced breast cancer: use of resources and cost implications. Brit J Cancer 1993; 67: 856–860.

Portenoy RK . Adjuvant analgesic agents. In: Cherny N , Foley K (eds). Hematology/Oncology Clinics of North America: Pain and Palliative Care 1996; 10: 103–119.

Tyrrell CJ , Collinson M , Madsen EL , Intravenous pamidronate: infusion rate and safety. Ann Oncol 1994; 5(Suppl. 7): 27–29.

Coleman RE , Purohit OP , Black C , Ibandronate: a well-tolerated new oral bisphosphonate for the treatment of bone metastases. Breast 1995; 4: 236.